Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...

DALLAS, TX, UNITED STATES, January 6, 2026 /EINPresswire.com/ -- The dental industry faces a critical inflection point: ...

Shirley MacFarland’s weekly community column featuring news and notes from Brecksville, Broadview Heights, North Royalton and ...

Precision Biosciences has outlined its key strategic objectives for the coming year, shifting investor focus squarely onto clinical execution. The company has confirmed a liquidity position it ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...

Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

PHOENIX — Jace Taylor is a rambunctious 4-year-old boy. He runs, jumps and plays with his friends. He isn’t aware that genetically, he’s different from other children. “I think he’s too young to ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...

As of Friday, January 09, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 6.99%, which has investors questioning ...

Fakeeh University Hospital is emerging as a global destination for advanced gene therapy, delivering highly specialized treatments for rare genetic ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.